T. Rowe Price Investment Management, Inc. Repligen Corp Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Repligen Corp stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 559,579 shares of RGEN stock, worth $67.9 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
559,579
Previous 260,848
114.52%
Holding current value
$67.9 Million
Previous $33.2 Million
109.7%
% of portfolio
0.04%
Previous 0.02%
Shares
12 transactions
Others Institutions Holding RGEN
# of Institutions
502Shares Held
58.2MCall Options Held
89.3KPut Options Held
679K-
Black Rock Inc. New York, NY7.57MShares$919 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.6MShares$802 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$616 Million0.01% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.91MShares$232 Million0.53% of portfolio
-
State Street Corp Boston, MA1.62MShares$197 Million0.01% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $6.74B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....